Opioid Crisis Fast Facts
Here’s a look at the opioid crisis.
Opioids are drugs formulated to replicate the pain-reducing properties of opium. Prescription painkillers like morphine, oxycodone and hydrocodone are opioids. Illegal drugs like heroin and illicitly made fentanyl are also opioids. The word “opioid” is derived from the word “opium.”
Common Opioids
Hydrocodone and oxycodone are semi-synthetic opioids, manufactured in labs with natural and synthetic ingredients.
Fentanyl is a fully synthetic opioid, originally developed as a powerful anesthetic for surgery. It is also administered to alleviate severe pain associated with terminal illnesses like cancer. The drug is up to 100 times more powerful than morphine. Just a small dose can be deadly. Illicitly produced fentanyl has been a driving factor in the number of overdose deaths in recent years.
Opioid Crisis Fast Facts
Here’s a look at the opioid crisis.
Opioids are drugs formulated to replicate the pain-reducing properties of opium. Prescription painkillers like morphine, oxycodone and hydrocodone are opioids. Illegal drugs like heroin and illicitly made fentanyl are also opioids. The word “opioid” is derived from the word “opium.”
Common Opioids
Hydrocodone and oxycodone are semi-synthetic opioids, manufactured in labs with natural and synthetic ingredients.
Fentanyl is a fully synthetic opioid, originally developed as a powerful anesthetic for surgery. It is also administered to alleviate severe pain associated with terminal illnesses like cancer. The drug is up to 100 times more powerful than morphine. Just a small dose can be deadly. Illicitly produced fentanyl has been a driving factor in the number of overdose deaths in recent years.
Opioid Crisis Fast Facts - ABC17NEWS abc17news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abc17news.com Daily Mail and Mail on Sunday newspapers.
FDA has not approved any biosimilars in 2021 after only approving three in 2020.
EMA approves second Novolog® (insulin aspartate), fifth Avastin® (bevacizumab), eighth Neulasta® (pegfilgrastim), and twelfth Humira® (adalimumab) biosimilars, and withdraws approval of an adalimumab biosimilar and a pegfilgrastim biosimilar.
Given the increasing number of approved biosimilars in Europe, biosimilar manufacturers are increasingly deciding to not market their products due to commercial reasons.
As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S. and European markets in the coming years. Global sales for the top ten branded biologic drugs totaled approximately $81 billion in 2019[1]. In a September 2020 report, the IQVIA Institute for Human Data Science estimated biosimilar sales totaling $80 billion over the next five years compared to $14 billion during the previous five years (2015-2
PHOENIX â Cancer screenings in the U.S. have plunged since the start of the pandemic almost a year ago, prompting health advocates to increase calls for the public to stop postponing these potentially life-saving procedures.
More than one-third of adults have failed to receive recommended cancer screenings during the pandemic, according to âCancer Wonât Wait and Neither Should You,â a bulletin published by the American Cancer Society and the National Comprehensive Cancer Network.
Fear of getting COVID-19 at screening centers and job losses that have affected insurance coverage are among the factors driving this dangerous trend.
âThe pandemic has really given cancer the advantage, and the balance of risk has shifted significantly,â Jeff Fehlis, executive vice president of the American Cancer Societyâs south region, said in an interview with Cronkite News.